Table 1 Characteristics of chordoma patients included in the whole-genome sequencing analysis (n = 80)a.

From: Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival

N (%)

Age (year)b

44.7 (7–79)

 ≤20

10 (12.5)

 20–40

21 (26.2)

 40–50

14 (17.5)

 50+

35 (43.8)

Sex

 F

30 (37.5)

 M

50 (62.5)

Histological type

 Classic

64 (80.0)

 Chondroid

14 (17.5)

 Dedifferentiated

2 (2.5)

Surgery type

 Endoscopic endonasal

78 (97.5)

 Open craniotomy

2 (2.5)

Gross resection rate

 Complete

16 (20.0)

 Near complete

36 (45.0)

 Subtotal or partial

28 (35.0)

Tumor volume (cm3)b

35.0 (4.2–147.5)

Presurgery RTc treatment

 No

68 (85.0)

 Yes

12 (15.0)

Post-surgery RTc treatment

 No

38 (47.5)

 Yes

42 (52.5)

Recurrence status

 No

21 (26.3)

 Yes

59 (73.7)

RFSd (month)b

21 (1–128)

Death status

 No

63 (78.8)

 Yes

17 (21.2)

Survival (month)b

50 (10–157)

  1. aNone of these patients received any chemo, immune, or targeted therapies.
  2. bCharacteristic in its continuous form is expressed as mean (range).
  3. cRadiation therapy.
  4. dRecurrence-free survival.
Back to article page